A stored sample may change because molecules associate into larger structures. That physical change is not equivalent to cleavage or another covalent modification, although several processes can occur in the same sample.
Aggregation is an observation with a time window
Onoue and colleagues aged glucagon and other peptide solutions under defined acidic conditions. They assessed assembly using several methods, including circular dichroism, electron microscopy, dye staining and size-exclusion chromatography.Onoue and colleagues — Ageing and glucagon fibril formation (opens in a new tab)
For glucagon, fibrillar structures appeared at different times depending on concentration. A condition showing no observed aggregation after one day did show fibrillar aggregates after longer ageing.Onoue and colleagues — Ageing and glucagon fibril formation (opens in a new tab)
The finding illustrates a basic limitation of an early negative observation. It describes that observation window; it cannot establish that a sample will remain unchanged over a substantially longer period.
The study conditions and materials remain part of the result. Its time points are not general storage allowances, and its comparison with other peptides does not rank the whole peptide class.
Less assembly does not guarantee less chemical change
Caputo and colleagues investigated glucagon degradation in an alkaline range chosen to reduce aggregation. They still found chemical modifications, including oxidation, deamidation and isomerisation, and compared selected modified forms in a bioassay.Caputo and colleagues — Mechanisms of glucagon degradation at alkaline pH (opens in a new tab)
Their findings separate several outcomes: fibrillation, chemical identity and biological response. Changes at different sites did not have a uniform effect on the measured activity.Caputo and colleagues — Mechanisms of glucagon degradation at alkaline pH (opens in a new tab)
A stability summary should preserve those distinctions. “Less aggregate” cannot be substituted for “more intact starting molecule” unless both were measured and the data support both statements.
Read the evidence as a set of complementary observations
| Observation | Interpretation still requiring care |
|---|---|
| A larger-size population appears | Its molecular composition and structure may remain unresolved. |
| Starting-peptide assay is unchanged | The method may not establish the assembly state. |
| No visible particles are reported | The visual observation does not cover every size range. |
| Both assembly and chemical assays change | More than one process may need to be described. |
For a hypothetical example, a sample retains its measured starting-peptide amount after an analytical preparation that disrupts assemblies. That result does not necessarily describe how molecules were organised inside the original stored sample.
The report should explain what each method receives and measures. Otherwise two apparently conflicting results may simply refer to different sample states or different analytical questions.
Do not force all results into a single “purity” percentage. Keeping the observations separate makes disagreements visible and helps identify which additional measurement would resolve them.
Describe the studied material rather than a general rule
A useful aggregation conclusion identifies the peptide, formulation, concentration, history, observation interval and detected assembly type. Where the structure remains unknown, use a description matching the evidence.
Distinguish an intentionally assembled research material from an unintended change during storage. The same broad word, aggregation, can appear in both contexts while the study objective differs.
Suitability for a planned experiment depends on its required material state. Neither a generic instruction to avoid all assembly nor a claim that aggregates are harmless can replace that requirement and the relevant measurements.
Sources and further detail
- Onoue and colleagues — Ageing and glucagon fibril formation (opens in a new tab)
Complete original 2004 abstract read. Only material-ageing and characterisation observations are summarised; no clinical extrapolation or preparation instructions.
- Caputo and colleagues — Mechanisms of glucagon degradation at alkaline pH (opens in a new tab)
Complete original 2013 abstract read. Chemical change, fibrillation and assay response are treated as different measured outcomes.
Sources checked 20 September 2026. Numerical examples are illustrative unless identified as published observations. This article has not undergone independent scientific peer review.